Loading...
Loading...
BCAB| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.3M |
| Gross Profit | -0.3M |
| Operating Expense | 28.9M |
| Operating I/L | -28.9M |
| Other Income/Expense | 1.5M |
| Interest Income | 1.5M |
| Pretax | -27.5M |
| Income Tax Expense | -1.5M |
| Net Income/Loss | -26.0M |
BioAtla, Inc. is a clinical stage biopharmaceutical company specializing in the development of specific antibody-based therapeutics for solid tumor cancer treatment. Their lead product candidate, BA3011, is a conditionally active biologic (CAB) antibody-drug conjugate (ADC) targeting soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, they are developing BA3021, a CAB ADC for multiple solid tumor types, and BA3071, a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for various cancers.
